Skip to Main Content

Author Details

Nima Aghdam
Beth Israel Deaconess Medical Center, Harvard Medical School
2005
39
13
PMIDPaper TitleJournal TitlePublished Year
37791195Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT).Cureus2023
38074646Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes.Front Oncol2023
37586844Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition.Mol Cancer Ther2023
34774650Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond.Radiother Oncol2022
35402242Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer.Front Oncol2022
35433457Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer.Front Oncol2022
36620537Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer.Front Oncol2022
35127506Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer.Front Oncol2022
35305936Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer.J Sex Med2022
33035622Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.Radiother Oncol2021
33718117Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer.Front Oncol2021
33493615Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.Int J Radiat Oncol Biol Phys2021
33489918Utilization of Iodinated SpaceOAR Vueâ¿¢ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal-Prostate Interface and Spare the Rectum: A Case Report.Front Oncol2021
33537236Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.Front Oncol2021
33842156Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.Cureus2021
34912703Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.Front Oncol2021
34585025Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series.Adv Radiat Oncol2021
34604059Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy.Front Oncol2021
32511873Ethnicity and insurance status predict metastatic disease presentation in prostate, breast, and non-small cell lung cancer.Cancer Med2020
32039015Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT).Front Oncol2020
33251131Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer.Front Oncol2020
33425723Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine Cancer.Front Oncol2020
32719744Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS â¿¥ 15).Front Oncol2020
32663537Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.Radiother Oncol2020
32311600Prostate bed and organ-at-risk deformation: Prospective volumetric and dosimetric data from a phase II trial of stereotactic body radiotherapy after radical prostatectomy.Radiother Oncol2020
32432033Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).Front Oncol2020
31108142Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials.Int J Radiat Oncol Biol Phys2019
31276777Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.Int J Radiat Oncol Biol Phys2019
30735235Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.JAMA Netw Open2019
28710895Erectile function after stereotactic body radiotherapy for localized prostate cancer.BJU Int2018
29487023Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer.Int J Radiat Oncol Biol Phys2018
28980407Social determinants of stage IV anal cancer and the impact of pelvic radiotherapy in the metastatic setting.Cancer Med2017
29052514Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.Radiat Oncol2017
26870697Radiation Metabolomics: Current Status and Future Directions.Front Oncol2016
28018523Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC).J Radiat Oncol2016
26403635High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations.Sci Rep2015
26433583Delayed postoperative C5 root palsy and the use of neurophysiologic monitoring.Eur Spine J2015
16841912Single-cell enzyme concentrations, kinetics, and inhibition analysis using high-density hydrodynamic cell isolation arrays.Anal Chem2006
15616739A novel high aspect ratio microfluidic design to provide a stable and uniform microenvironment for cell growth in a high throughput mammalian cell culture array.Lab Chip2005
  • 1 - 39 of 39

Recommended Authors

Chenyang Wang
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Career Start Year 2017
Number of shared co-authors 18
Kristina Commisso
University Health Network
Career Start Year 2016
Number of shared co-authors 2
Luca F Valle
University of California los angeles
Career Start Year 2016
Number of shared co-authors 25
Andrew Warner
Western University and London Regional Cancer Program
Career Start Year 2013
Number of shared co-authors 2
Kiri A Sandler
Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 20
Stephen Greco
Johns Hopkins University School of Medicine
Career Start Year 2012
Number of shared co-authors 25
Darlene Veruttipong
Stanford University
Career Start Year 2012
Number of shared co-authors 7
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Career Start Year 2011
Number of shared co-authors 11
Ting Martin Ma
University of Washington
Career Start Year 2010
Number of shared co-authors 32
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 13
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 3
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 3
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 4
Bradley J Stish
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 25
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 12
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 2006
Number of shared co-authors 19
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 3
Himanshu Nagar
New York-Presbyterian Hospital, Weill Cornell Medical Center
Career Start Year 2005
Number of shared co-authors 10
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Career Start Year 2004
Number of shared co-authors 26
Piet Ost
Ghent University, GZA Ziekenhuizen
Career Start Year 2002
Number of shared co-authors 15
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 2
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 1
Drew Moghanaki
University of California Los Angeles
Career Start Year 2000
Number of shared co-authors 6
Chandana A Reddy
Cleveland Clinic
Career Start Year 2000
Number of shared co-authors 25
Daniel J Krauss
William Beaumont School of Medicine
Career Start Year 1999
Number of shared co-authors 21
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 17
Jonathan D Tward
Huntsman Cancer Institute, University of Utah
Career Start Year 1994
Number of shared co-authors 21
Jeff M Michalski
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 26
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 24
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1976
Number of shared co-authors 28

Collaborators

Sean P Collins
Vanderbilt University School of Medicine
Co-authored papers 30
Simeng Suy
MedStar Georgetown University Hospital
Co-authored papers 27
Michael L Steinberg
University of California los angeles
Co-authored papers 9
Amar U Kishan
University of California los angeles
Co-authored papers 9
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 8
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 6
Alan W Katz
University of Rochester
Co-authored papers 6
Donald B Fuller
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Co-authored papers 6
Hilary P Bagshaw
Stanford University
Co-authored papers 6
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 6
Ye Yuan
Southwest Hospital, Army Medical University
Co-authored papers 6
Constantine A Mantz
University of Chicago
Co-authored papers 6
Mark K Buyyounouski
Stanford University
Co-authored papers 6
Naomi Y Jiang
University of California los angeles
Co-authored papers 5
David Shabsovich
university of california los angeles Medical Center
Co-authored papers 4
Leszek Miszczyk
MSC National Research Institute of Oncology Gliwice Branch
Co-authored papers 4
Audrey Dang
Tulane University School of Medicine
Co-authored papers 4
William C Jackson
University of Michigan ann arbor
Co-authored papers 4
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Co-authored papers 3
Fang-I Chu
David Geffen School of Medicine, University of California los angeles
Co-authored papers 3
Christopher R King
University of California los angeles
Co-authored papers 3
Rebecca Levin-Epstein
University of California los angeles
Co-authored papers 3
Minsong Cao
University of California Los Angeles
Co-authored papers 3
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 3
Agnieszka Namys??-Kaletka
Maria Sklodowska-Curie National Research and Institute of Oncology
Co-authored papers 3
Nicholas G Zaorsky
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Co-authored papers 3
Aleksandra Napieralska
MSC National Research Institute of Oncology Gliwice Branch
Co-authored papers 3
Shrinivasa K Upadhyaya
University of California davis
Co-authored papers 2
Tahmineh Romero
David Geffen School of Medicine at university of california los angeles
Co-authored papers 2
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2
Release 1.2